FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
A new report by the Federal Trade Commission says pharmacy benefit management companies are driving up your out-of-pocket costs for prescription drugs.
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Newsweek on MSN12d
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report ClaimsThe FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback